UNITED STATES
 
SECURITIES AND EXCHANGE COMMISSION
 
Washington, D.C. 20549
 
 
FORM 6-K
 
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934
 
For the month of January 2025
 
Commission File Number: 001-41411
 
Haleon plc
(Translation of registrant’s name into English)
 
Building 5, First Floor, The Heights,
Weybridge, Surrey, KT13 0NY
(Address of principal executive offices)
 
 
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
 
 
Form 20-F
 
Form 40-F
 
 
 
EXHIBIT INDEX
 
Exhibit Number
Description
99.1
17 January 2025 - “Holding(s) in Company”
 
 
99.1
 
 
17 January 2025   
 
HALEON PLC 
("Haleon" or "the Company")  
 
TR-1: Standard form for notification of major holdings
 
1. Issuer Details
 
ISIN
 
GB00BMX86B70
 
 
Issuer Name
 
HALEON PLC
 
 
UK or Non-UK Issuer
 
UK
 
 
2. Reason for Notification
 
An acquisition or disposal of voting rights
 
 
3. Details of person subject to the notification obligation
 
Name
 
Pfizer Inc.
 
 
City of registered office (if applicable)
 
New York
 
 
Country of registered office (if applicable)
 
United States of America
 
 
4. Details of the shareholder
 
 
Name
 
City of registered office
Country of registered office
State Street Nominees Limited
 
London
 
United Kingdom
 
Guaranty Nominees Limited
 
London
 
United Kingdom
 
 
5. Date on which the threshold was crossed or reached
 
17-Jan-2025
 
 
6. Date on which Issuer notified
 
17-Jan-2025
 
 
7. Total positions of person(s) subject to the notification obligation
 
 
 
% of voting rights attached to shares (total of 8.A)
 
% of voting rights through financial instruments (total of 8.B 1 + 8.B 2)
Total of both in % (8.A + 8.B)
Total number of voting rights held in issuer
Resulting situation on the date on which threshold was crossed or reached
 
7.310000
 
0.000000
 
7.310000
 
661709764
 
Position of previous notification (if applicable)
 
15.040000
 
0.000000
 
15.040000
 
 
 
8. Notified details of the resulting situation on the date on which the threshold was crossed or reached
 
8A. Voting rights attached to shares
 
 
Class/Type of shares ISIN code(if possible)
 
Number of direct voting rights (DTR5.1)
Number of indirect voting rights (DTR5.2.1)
% of direct voting rights (DTR5.1)
% of indirect voting rights (DTR5.2.1)
Ordinary Shares GB00BMX86B70
 
 
267251860
 
 
2.950000
 
Restricted ADSs
 
 
394457904
 
 
4.360000
 
Sub Total 8.A
661709764
 
7.310000%
 
 
8B1. Financial Instruments according to (DTR5.3.1R.(1) (a))
 
Type of financial instrument
Expiration date
Exercise/conversion period
 
Number of voting rights that may be acquired if the instrument is exercised/converted
 
% of voting rights
 
 
 
 
 
 
Sub Total 8.B1
 
 
 
 
 
8B2. Financial Instruments with similar economic effect according to (DTR5.3.1R.(1) (b))
 
Type of financial instrument
Expiration date
 
Exercise/conversion period
 
Physical or cash settlement
Number of voting rights
% of voting rights
 
 
 
 
 
 
 
Sub Total 8.B2
 
 
 
 
 
9. Information in relation to the person subject to the notification obligation
 
1. Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer.
 
 
 
Ultimate controlling person
Name of controlled undertaking
 
% of voting rights if it equals or is higher than the notifiable threshold
 
% of voting rights through financial instruments if it equals or is higher than the notifiable threshold
Total of both if it equals or is higher than the notifiable threshold
 
 
 
 
 
 
 
10. In case of proxy voting
 
Name of the proxy holder
 
 
 
 
The number and % of voting rights held
 
 
 
 
The date until which the voting rights will be held
 
 
 
 
11. Additional Information
 
This notification relates to the sale by Pfizer Inc. ("Pfizer") of a portion of its interest in Haleon plc ("Haleon").
 
Pfizer sold 700,000,000 Haleon ordinary shares pursuant to a secondary offering announced on 14 January 2025.
 
These calculations are based on Haleon's issued voting share capital of 9,053,360,882 ordinary shares with voting rights, as communicated by Haleon in their announcement on total voting rights and capital dated 1 November 2024.
 
Pfizer holds its ordinary shares in Haleon through (i) State Street Nominees Limited, and (ii) Guaranty Nominees Limited (in respect of its American depositary shares representing ordinary shares), which hold the legal title to those shares on Pfizer's behalf.
 
 
12. Date of Completion
 
17-Jan-2025
 
 
13. Place Of Completion
 
New York, USA
 
 
Amanda Mellor, Company Secretary
 
 
 
 
 
SIGNATURE
 
 
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
 
 
 
HALEON PLC
   (Registrant)
 
Date: January 17, 2025
By:
/s/ Amanda Mellor
 
 
Name:
Amanda Mellor
 
 
Title:
Company Secretary

Haleon (PK) (USOTC:HLNCF)
Graphique Historique de l'Action
De Jan 2025 à Fév 2025 Plus de graphiques de la Bourse Haleon (PK)
Haleon (PK) (USOTC:HLNCF)
Graphique Historique de l'Action
De Fév 2024 à Fév 2025 Plus de graphiques de la Bourse Haleon (PK)